GlassScriptPhysician profile
Talal Mohammed Sayed Dahab
NPI 1619506185
$5,678.24
in general payments reported to CMS, 2019-2025
10 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,448 · 2024: $2,735 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $1,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $1,678.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,087.37 | 2023-2024 | Davinci Xi |
| Davol INC. | $429.79 | 2023-2025 | Phasix Mesh |
| Boston Scientific Corporation | $243.63 | 2023-2024 | Exalt Model D, Spyglass Discover, Spyglass |
| Abbvie INC. | $204.78 | 2023-2025 | Strattice Reconstructive Tissue Matrix Bps |
| Acera Surgical, INC. | $151.12 | 2025 | Restrata Wound Matrix |
| Integra Lifesciences Corporation | $146.63 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Medtronic, INC. | $142.84 | 2023 | Endurant Iis |
| W. L. Gore & Associates, INC. | $125.00 | 2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Kerecis Limited | $103.84 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Lemaitre Vascular, INC. | $43.24 | 2024 | Artegraft Vascular Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talal Dahab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.